Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MGLL | Q99685 | 4/20 | 0.60 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | FAAH | O00519 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21722822 | 0.86 | SLC2A1 (0.59) | HTTMGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL21722836 | 0.85 | SIGMAR1 (0.60) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL14389738 | 0.83 | CYP1A2 (0.65) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL9058527 | 0.82 | CYP1A2 (0.61) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL12794615 | 0.81 | MGLL (0.87) | LMNASMN1; SMN2MAPTTDP1MGLL | |
| SCHEMBL25075298 | 0.80 | CYP1A2 (0.71) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL1242937 | 0.80 | CYP1A2 (0.61) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL2103545 | 0.80 | CYP1A2 (0.70) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL3455702 | 0.80 | HTT (0.91) | HTTLMNASMN1; SMN2MAPTMAPK1 | |
| SCHEMBL21381823 | 0.79 | MGLL (0.68) | MGLLCYP1A2CYP2D6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936503-A | Oxazin monoacylglycerol lipase (MAGL) inhibitors | 豪夫迈·罗氏有限公司 | 2020-11-13 | — | — | CN | disclosed |
| EP-2373344-B1 | COMBINED DRUG ADMINISTRATION | HOFFMANN LA ROCHE (CH) | 2016-03-30 | — | — | EP | disclosed |
| US-20160074360-A1 | COMBINED DRUG ADMINISTRATION OF DALCETRAPIB AND ORLISTAT | HOFFMANN-LA ROCHE INC. | 2016-03-17 | — | — | US | disclosed |
| EP-2373344-A1 | COMBINED DRUG ADMINISTRATION | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010066593-A1 | COMBINED DRUG ADMINISTRATION | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144853-A1 | NOVEL COMBINED ADMINISTRATION | HOFFMANN-LA ROCHE, INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144853-A1 | NOVEL COMBINED ADMINISTRATION | CES1, PCSK9, LIPG | HTT 3209/4885LMNA 1122/4885SMN1; SMN2 1966/4885 |
| US-20160074360-A1 | COMBINED DRUG ADMINISTRATION OF DALCETRAPIB AND ORLISTAT | CETP, MTTP, LIPC | HTT 1654/4885LMNA 1246/4885SMN1; SMN2 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.